Discover how dynamic BH3 profiling can predict responses in lung cancer patients to ALK inhibitors, enhancing personalized ...

Ensacove is FDA-approved to treat non-small-cell lung cancer (NSCLC) in adults whose cancer meets all of the following requirements: ALK-positive, which means the cancer has certain abnormal ...

An isogenic cell line was created to model cancer ... ALK. We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Although immunotherapies and biomarker-driven interventions have transformed lung cancer outcomes, Martin Edelman, MD, Fox Chase Cancer Center, highlighted the present challenge hindering clinicians' ...

EGFR mutations account for approximately 10-15% of lung cancer in the U.S. and are more frequently found in non-smokers, ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

NSCLC is the most prevalent form of lung cancer. This approval in the European ... and do not have anaplastic lymphoma kinase (ALK) rearrangements or epidermal growth factor receptor (EGFR ...